破傷風トキソイドワクチンの世界市場レポート 2025年

破傷風トキソイドワクチン市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は7.2%で、72億2,000万米ドルに成長します。予測期間の成長は、研究開発への投資の増加、流通網の拡大に起因しています。予測期間の主要動向としては、ワクチン技術の進歩、新興市場、新製品・サービスの発売、ワクチン需要の拡大などが挙げられます。

早産率の上昇が、今後数年間の破傷風トキソイドワクチン市場の成長を牽引すると予想されます。早産とは、赤ちゃんが妊娠37週を迎える前に生まれることを指し、不完全な開発により様々な健康合併症を引き起こす可能性があります。早産の問題は、母親の年齢の上昇、ライフスタイルの選択、生殖補助医療のような医療介入、母親の健康状態、環境の影響などの要因に影響されます。早産率が上昇するにつれ、破傷風やその他の予防可能な病気から身を守るために予防接種を必要とする新生児や乳児が増えるため、破傷風トキソイドワクチンの需要が増加しています。例えば、2022年12月、英国を拠点とする妊娠・出産ロスの調査に特化した団体Tommy'sは、英国における生前早産の割合が2021年の7.5％から2022年には7.9％に上昇したと報告しています。このように、早産率の増加が破傷風トキソイドワクチン市場の拡大に拍車をかけています。

破傷風トキソイドワクチン市場の主要企業は、包括的な予防接種ソリューションに対する需要の増加に対応するため、wP-IPVベースの5価ワクチンなどの新興国ワクチンの開発に注力しています。wP-IPVベースの5価ワクチンは、複数の疾病予防を1回の注射で可能にするもので、不活化細菌やウイルスを使用し、疾病を引き起こすことなく免疫を刺激します。例えば、Panacea BIoTec Limitedは2023年12月に、ジフテリア、破傷風、百日咳、ポリオ、B型インフルエンザを予防する完全液状の5価ワクチンEasyFourPolを発売しました。このワクチンは、現場での調製が不要なため投与が簡素化され、効率的かつ効果的な予防接種が可能となります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の破傷風トキソイドワクチンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の破傷風トキソイドワクチン市場：成長率分析
• 世界の破傷風トキソイドワクチン市場の実績：規模と成長、2019～2024年
• 世界の破傷風トキソイドワクチン市場の予測：規模と成長、2024～2029年、2034年
• 世界の破傷風トキソイドワクチン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の破傷風トキソイドワクチン市場ワクチンタイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 破傷風トキソイド（TT）
• ジフテリアと破傷風（DT）
• 破傷風とジフテリア（TD）
• ジフテリア・破傷風・百日咳（Dtap）
• 破傷風・ジフテリア・百日咳（Tdap）
• 五価
• 六価
• その他
• 世界の破傷風トキソイドワクチン市場：年齢層別、実績と予測、2019～2024年、2024～2029年、2034年
• 小児科
• 成人用
• 世界の破傷風トキソイドワクチン市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院とクリニック
• 政府機関
• その他
• 世界の破傷風トキソイドワクチン市場、破傷風トキソイド（TT）のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 成人用破傷風トキソイドワクチン
• 小児用破傷風トキソイドワクチン
• 世界の破傷風トキソイドワクチン市場、ジフテリアと破傷風（DT）のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 小児用ジフテリアと破傷風ワクチン
• 成人用ジフテリアと破傷風ワクチン
• 世界の破傷風トキソイドワクチン市場、破傷風とジフテリア（Td）のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ブースターTDワクチン
• 成人用TDワクチン
• 妊婦用TDワクチン
• 世界の破傷風トキソイドワクチン市場、ジフテリア・破傷風・百日咳（Dtap）のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 小児用Dtapワクチン
• 乳児用Dtap混合ワクチン
• 世界の破傷風トキソイドワクチン市場、破傷風・ジフテリア・百日咳（Tdap）のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 青少年用Tdapワクチン
• 成人用Tdapワクチン
• 世界の破傷風トキソイドワクチン市場、五価のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 乳児用五価ワクチン（ジフテリア、破傷風、百日咳、B型肝炎、ヒブを含む）
• 世界の破傷風トキソイドワクチン市場、六価のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 乳児用6価ワクチン（ジフテリア、破傷風、百日咳、B型肝炎、ヒブ、ポリオを含む）
• 世界の破傷風トキソイドワクチン市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 追加抗原を含む混合ワクチン
• 特定の人口集団（妊婦、旅行者）向けのワクチン

第7章 地域別・国別分析

• 世界の破傷風トキソイドワクチン市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の破傷風トキソイドワクチン市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 破傷風トキソイドワクチン市場：競合情勢
• 破傷風トキソイドワクチン市場：企業プロファイル
  • Sanofi S.A.
  • Novartis AG
  • LG Chem Ltd.
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited

第31章 その他の大手企業と革新的企業

• Merck KGaA
• Astellas Pharma Inc.
• CSL Limited
• Zoetis Inc.
• Meiji Holdings Company Ltd.
• Walvax BIoTechnology
• Shenzhen Kangtai Biological Products Co. Ltd.
• AJ Vaccines AS
• PT Bio Farma
• Serum Institute of India Pvt. Ltd.
• Bharat BIoTech International Limited
• Panacea BIoTec Ltd.
• Amson Vaccines and Pharma Pvt Ltd.
• Incepta Vaccine Ltd.
• Mitsubishi Tanabe Pharma Corporation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 破傷風トキソイドワクチン市場、2029年：新たな機会を提供する国
• 破傷風トキソイドワクチン市場、2029年：新たな機会を提供するセグメント
• 破傷風トキソイドワクチン市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

The tetanus toxoid vaccine is designed to prevent tetanus, a severe bacterial infection caused by Clostridium tetani. It contains a form of the tetanus toxin, known as toxoid, which is harmless but prompts the immune system to generate antibodies against the toxin. These antibodies work by neutralizing the toxin produced by the bacteria, thereby providing protection against future infections.

The various types of tetanus toxoid vaccines are available. These include tetanus toxoid (Tt), diphtheria and tetanus (Dt), tetanus and diphtheria (Td), diphtheria, tetanus, and pertussis (Dtap), tetanus, diphtheria, and pertussis (Tdap), pentavalent, hexavalent, and others. Tetanus toxoid (Tt) vaccines consist of purified tetanus toxoid that stimulates the immune system to defend against tetanus-causing bacteria. These vaccines are used across different age groups, from pediatric to adult, in hospitals, clinics, government organizations, and other healthcare settings.

The tetanus toxoid vaccine market research report is one of a series of new reports from The Business Research Company that provides tetanus toxoid vaccine market statistics, including the tetanus toxoid vaccine industry global market size, regional shares, competitors with tetanus toxoid vaccine market share, detailed tetanus toxoid vaccine market segments, market trends, and opportunities, and any further data you may need to thrive in the tetanus toxoid vaccine industry. These tetanus toxoid vaccine market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tetanus toxoid vaccine market size has grown strongly in recent years. It will grow from $5.08 billion in 2024 to $5.46 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to increasing awareness, rising incidence of tetanus cases, and government initiatives for immunization programs.

The tetanus toxoid vaccine market size is expected to see strong growth in the next few years. It will grow to $7.22 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing investments in research and development, and expanding distribution networks. Major trends in the forecast period include advancements in vaccine technology, emerging markets, launches of new products and services, and growing demand for vaccines.

The rising rates of preterm births are expected to drive the growth of the tetanus toxoid vaccine market in the coming years. Preterm birth refers to when a baby is born before completing 37 weeks of gestation, which can lead to various health complications due to incomplete development. The issue of preterm birth is influenced by factors such as increased maternal age, lifestyle choices, medical interventions like assisted reproductive technologies, maternal health conditions, and environmental influences. As preterm birth rates rise, there is an increased demand for tetanus toxoid vaccines, as more newborns and infants require immunization to protect against tetanus and other preventable diseases. For example, in December 2022, Tommy's, a UK-based organization focused on pregnancy and baby loss research, reported that the percentage of live preterm births in the United Kingdom rose from 7.5% in 2021 to 7.9% in 2022. Thus, the growing preterm birth rates are fueling the expansion of the tetanus toxoid vaccine market.

Leading companies in the tetanus toxoid vaccine market are focusing on developing advanced vaccines, such as the wP-IPV-based pentavalent vaccine, to meet increasing demand for comprehensive immunization solutions. The wP-IPV-based pentavalent vaccine combines multiple disease protections into a single injection, using inactivated bacteria and viruses to stimulate immunity without causing illness. For instance, Panacea Biotec Limited launched EasyFourPol in December 2023, a fully-liquid pentavalent vaccine that protects against Diphtheria, Tetanus, Pertussis, Polio, and Haemophilus Influenza Type B infections. This vaccine simplifies administration by eliminating the need for on-site preparation, ensuring efficient and effective immunization.

In January 2024, the Serum Institute of India Pvt. Ltd., an India-based vaccine manufacturing company, formed a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) network. The collaboration aims to speed up the development and production of affordable vaccines, strengthening global health security and ensuring equitable access during future disease outbreaks. The Coalition for Epidemic Preparedness Innovations is a Norway-based organization dedicated to advancing the development of vaccines.

Major companies operating in the tetanus toxoid vaccine market are Sanofi S.A., Novartis AG, LG Chem Ltd., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Merck KGaA, Astellas Pharma Inc., CSL Limited, Zoetis Inc., Meiji Holdings Company Ltd., Walvax Biotechnology, Shenzhen Kangtai Biological Products Co. Ltd., AJ Vaccines AS, PT Bio Farma, Serum Institute of India Pvt. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Amson Vaccines and Pharma Pvt Ltd., Incepta Vaccine Ltd., Mitsubishi Tanabe Pharma Corporation, BioNet-Asia Co. Ltd., Avalon Pharma Pvt. Ltd., Actiza Pharmaceutical Pvt. Ltd

North America was the largest region in the tetanus toxoid vaccine market in 2024. The regions covered in the tetanus toxoid vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the tetanus toxoid vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tetanus toxoid vaccine market consists of sales of live, attenuated, inactivated, subunit, conjugate, and toxoid vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tetanus Toxoid Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tetanus toxoid vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tetanus toxoid vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tetanus toxoid vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Vaccine Type: Tetanus Toxoid (TT); Diphtheria And Tetanus (DT); Tetanus And Diphtheria (Td); Diphtheria, Tetanus, And Pertussis (Dtap); Tetanus, Diphtheria, And Pertussis (Tdap); Pentavalent; Hexavalent; Other Types
• 2) By Age Group: Pediatric; Adult
• 3) By End-User: Hospitals And Clinics; Government Organizations; Other End-Users
• Subsegments:
• 1) By Tetanus Toxoid (TT): Adult Tetanus Toxoid Vaccine; Pediatric Tetanus Toxoid Vaccine
• 2) By Diphtheria And Tetanus (DT): Pediatric Diphtheria And Tetanus Vaccine; Adult Diphtheria And Tetanus Vaccine
• 3) By Tetanus And Diphtheria (Td): Booster Td Vaccines; Td Vaccines For Adults; Td Vaccines For Pregnant Women
• 4) By Diphtheria, Tetanus, And Pertussis (Dtap): Pediatric Dtap Vaccine; Dtap Combination Vaccine For Infants
• 5) By Tetanus, Diphtheria, And Pertussis (Tdap): Tdap Vaccine For Adolescents; Tdap Vaccine For Adults
• 6) By Pentavalent: Pentavalent Vaccine For Infants (Including Diphtheria, Tetanus, Pertussis, Hepatitis B, And Hib)
• 7) By Hexavalent: Hexavalent Vaccine For Infants (Including Diphtheria, Tetanus, Pertussis, Hepatitis B, Hib, And Polio)
• 8) By Other Types: Combination Vaccines With Additional Antigens; Vaccines For Specific Population Groups (Pregnant Women, Travelers)
• Companies Mentioned: Sanofi S.A.; Novartis AG; LG Chem Ltd.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Tetanus Toxoid Vaccine Market Characteristics

3. Tetanus Toxoid Vaccine Market Trends And Strategies

4. Tetanus Toxoid Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Tetanus Toxoid Vaccine Growth Analysis And Strategic Analysis Framework

• 5.1. Global Tetanus Toxoid Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Tetanus Toxoid Vaccine Market Growth Rate Analysis
• 5.4. Global Tetanus Toxoid Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Tetanus Toxoid Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Tetanus Toxoid Vaccine Total Addressable Market (TAM)

6. Tetanus Toxoid Vaccine Market Segmentation

• 6.1. Global Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tetanus Toxoid (TT)
• Diphtheria And Tetanus (DT)
• Tetanus And Diphtheria (Td)
• Diphtheria, Tetanus, And Pertussis (Dtap)
• Tetanus, Diphtheria, And Pertussis (Tdap)
• Pentavalent
• Hexavalent
• Other Types
• 6.2. Global Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric
• Adult
• 6.3. Global Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Government Organizations
• Other End-Users
• 6.4. Global Tetanus Toxoid Vaccine Market, Sub-Segmentation Of Tetanus Toxoid (TT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adult Tetanus Toxoid Vaccine
• Pediatric Tetanus Toxoid Vaccine
• 6.5. Global Tetanus Toxoid Vaccine Market, Sub-Segmentation Of Diphtheria And Tetanus (DT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric Diphtheria And Tetanus Vaccine
• Adult Diphtheria And Tetanus Vaccine
• 6.6. Global Tetanus Toxoid Vaccine Market, Sub-Segmentation Of Tetanus And Diphtheria (Td), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Booster Td Vaccines
• Td Vaccines For Adults
• Td Vaccines For Pregnant Women
• 6.7. Global Tetanus Toxoid Vaccine Market, Sub-Segmentation Of Diphtheria, Tetanus, And Pertussis (Dtap), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric Dtap Vaccine
• Dtap Combination Vaccine For Infants
• 6.8. Global Tetanus Toxoid Vaccine Market, Sub-Segmentation Of Tetanus, Diphtheria, And Pertussis (Tdap), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tdap Vaccine For Adolescents
• Tdap Vaccine For Adults
• 6.9. Global Tetanus Toxoid Vaccine Market, Sub-Segmentation Of Pentavalent, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pentavalent Vaccine For Infants (Including Diphtheria, Tetanus, Pertussis, Hepatitis B, And Hib)
• 6.10. Global Tetanus Toxoid Vaccine Market, Sub-Segmentation Of Hexavalent, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hexavalent Vaccine For Infants (Including Diphtheria, Tetanus, Pertussis, Hepatitis B, Hib, And Polio)
• 6.11. Global Tetanus Toxoid Vaccine Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Combination Vaccines With Additional Antigens
• Vaccines For Specific Population Groups (Pregnant Women, Travelers)

7. Tetanus Toxoid Vaccine Market Regional And Country Analysis

• 7.1. Global Tetanus Toxoid Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Tetanus Toxoid Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Tetanus Toxoid Vaccine Market

• 8.1. Asia-Pacific Tetanus Toxoid Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Tetanus Toxoid Vaccine Market

• 9.1. China Tetanus Toxoid Vaccine Market Overview
• 9.2. China Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Tetanus Toxoid Vaccine Market

• 10.1. India Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Tetanus Toxoid Vaccine Market

• 11.1. Japan Tetanus Toxoid Vaccine Market Overview
• 11.2. Japan Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Tetanus Toxoid Vaccine Market

• 12.1. Australia Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Tetanus Toxoid Vaccine Market

• 13.1. Indonesia Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Tetanus Toxoid Vaccine Market

• 14.1. South Korea Tetanus Toxoid Vaccine Market Overview
• 14.2. South Korea Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Tetanus Toxoid Vaccine Market

• 15.1. Western Europe Tetanus Toxoid Vaccine Market Overview
• 15.2. Western Europe Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Tetanus Toxoid Vaccine Market

• 16.1. UK Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Tetanus Toxoid Vaccine Market

• 17.1. Germany Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Tetanus Toxoid Vaccine Market

• 18.1. France Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Tetanus Toxoid Vaccine Market

• 19.1. Italy Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Tetanus Toxoid Vaccine Market

• 20.1. Spain Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Tetanus Toxoid Vaccine Market

• 21.1. Eastern Europe Tetanus Toxoid Vaccine Market Overview
• 21.2. Eastern Europe Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Tetanus Toxoid Vaccine Market

• 22.1. Russia Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Tetanus Toxoid Vaccine Market

• 23.1. North America Tetanus Toxoid Vaccine Market Overview
• 23.2. North America Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Tetanus Toxoid Vaccine Market

• 24.1. USA Tetanus Toxoid Vaccine Market Overview
• 24.2. USA Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Tetanus Toxoid Vaccine Market

• 25.1. Canada Tetanus Toxoid Vaccine Market Overview
• 25.2. Canada Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Tetanus Toxoid Vaccine Market

• 26.1. South America Tetanus Toxoid Vaccine Market Overview
• 26.2. South America Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Tetanus Toxoid Vaccine Market

• 27.1. Brazil Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Tetanus Toxoid Vaccine Market

• 28.1. Middle East Tetanus Toxoid Vaccine Market Overview
• 28.2. Middle East Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Tetanus Toxoid Vaccine Market

• 29.1. Africa Tetanus Toxoid Vaccine Market Overview
• 29.2. Africa Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Tetanus Toxoid Vaccine Market Competitive Landscape And Company Profiles

• 30.1. Tetanus Toxoid Vaccine Market Competitive Landscape
• 30.2. Tetanus Toxoid Vaccine Market Company Profiles
  • 30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. LG Chem Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

31. Tetanus Toxoid Vaccine Market Other Major And Innovative Companies

• 31.1. Merck KGaA
• 31.2. Astellas Pharma Inc.
• 31.3. CSL Limited
• 31.4. Zoetis Inc.
• 31.5. Meiji Holdings Company Ltd.
• 31.6. Walvax Biotechnology
• 31.7. Shenzhen Kangtai Biological Products Co. Ltd.
• 31.8. AJ Vaccines AS
• 31.9. PT Bio Farma
• 31.10. Serum Institute of India Pvt. Ltd.
• 31.11. Bharat Biotech International Limited
• 31.12. Panacea Biotec Ltd.
• 31.13. Amson Vaccines and Pharma Pvt Ltd.
• 31.14. Incepta Vaccine Ltd.
• 31.15. Mitsubishi Tanabe Pharma Corporation

32. Global Tetanus Toxoid Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Tetanus Toxoid Vaccine Market

34. Recent Developments In The Tetanus Toxoid Vaccine Market

35. Tetanus Toxoid Vaccine Market High Potential Countries, Segments and Strategies

• 35.1 Tetanus Toxoid Vaccine Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Tetanus Toxoid Vaccine Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Tetanus Toxoid Vaccine Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer